Therapeutic Consequences of Targeting the IGF-1/PI3K/AKT/FOXO3 Axis in Sarcopenia: A Narrative Review
Benjamin Gellhaus, Kai O. Böker, Arndt F. Schilling, Dominik Saul · 2023
Read Therapeutic Consequences of Targeting the IGF-1/PI3K/AKT/FOXO3 Axis in Sarcopenia: A Narrative Review by Benjamin Gellhaus, Kai O. Böker, Arndt F. Schilling, Dominik Saul (2023) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-10741475.txt.
Description
Benjamin Gellhaus and co-authors review a growth pathway as a drug target for age-related muscle loss in a paper from 2023. Sarcopenia thins muscle in old age, raising fall and hospital risk. Exercise is the proven therapy, yet injured or immobile patients cannot do enough of it. New drug routes are needed.
A switch protein called FOXO3 sits at the pathway's end. In wasting muscle it turns on two enzymes that tag muscle protein for destruction. Turning FOXO3 down in studies grew muscle fibers larger. The review weighs gene therapy aimed at this switch, plus its risks. A molecular brake on wasting could serve patients whom exercise cannot reach.
Catalog record
| CREATOR | Benjamin Gellhaus, Kai O. Böker, Arndt F. Schilling, Dominik Saul |
|---|---|
| YEAR | 2023 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 44 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |